The charts on this page feature a breakdown of the total annual pay for the top executives at ALNYLAM PHARMACEUTICALS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ALNYLAM PHARMACEUTICALS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ALNYLAM PHARMACEUTICALS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
John M. Maraganore Ph.D.
Former Chief Executive Officer (principal executive officer)
Total Cash $2,044,220 Equity $7,861,410 Other $271,055 Total Compensation $10,176,685
Akshay K. Vaishnaw M.D.Ph.D.
President, Research and Development
Total Cash $1,070,350 Equity $4,339,785 Other $14,900 Total Compensation $5,425,035
Yvonne L. Greenstreet MBChB, MBA
President and Chief Operating Officer
Total Cash $1,048,220 Equity $7,341,000 Other $186,000 Total Compensation $8,575,220
Jeffrey V. Poulton
Executive Vice President, Chief Financial Officer (principal financial officer)
Total Cash $899,830 Equity $1,884,125 Other $14,220 Total Compensation $2,798,175
Tolga Tanguler
Executive Vice President, Chief Commercial Officer
Total Cash $864,150 Equity $6,001,330 Other $11,710 Total Compensation $6,877,190
For its 2021 fiscal year, ALNYLAM PHARMACEUTICALS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
John M. Maraganore Ph.D. CEO Pay $10,176,685 Median Employee Pay $231,163 CEO Pay Ratio 44:1
For its 2021 fiscal year, ALNYLAM PHARMACEUTICALS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Amy W. Schulman Total Cash $699,016
Colleen F. Reitan Total Cash $467,452
David E.I. Pyott Total Cash $469,952
Dennis A. Ausiello, M.D. Total Cash $469,952
Margaret A. Hamburg, M.D. Total Cash $465,577
Marsha H. Fanucci Total Cash $487,452
Michael W. Bonney Total Cash $4,464,126
Olivier Brandicourt, M.D. Total Cash $470,160
Phillip A. Sharp, Ph.D. Total Cash $492,869
Steven M. Paul, M.D. Total Cash $472,452

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.